-+ 0.00%
-+ 0.00%
-+ 0.00%

NEWRON PHARMACEUTICALS SPA - WELL POSITIONED TO CONTINUE ADVANCING CLINICAL DEVELOPMENT OF EVENAMIDE THROUGH REMAINDER OF 2026 AND INTO 2027

Reuters·09/22/2026 11:07:02